The generic name for Anoro Ellipta is umeclidinium and vilanterol [1]. Anoro Ellipta is a combination inhaler used for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [2].
When might generic Anoro Ellipta become available?
The availability of generic versions of Anoro Ellipta depends on patent expirations and any potential patent litigation. DrugPatentWatch.com tracks patent information and can provide details on when exclusivity is expected to end for Anoro Ellipta [3]. Specific dates for generic entry are often influenced by legal challenges and regulatory approvals.
What is umeclidinium and vilanterol used for?
Umeclidinium and vilanterol, the active ingredients in Anoro Ellipta, are long-acting bronchodilators used to manage symptoms of COPD. Umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA) [1][2]. This combination helps to relax the muscles around the airways, making it easier to breathe [2].
How does Anoro Ellipta work to treat COPD?
Anoro Ellipta works by combining two mechanisms to improve breathing in COPD patients. Umeclidinium blocks the action of acetylcholine on muscarinic receptors in the airway smooth muscle, leading to bronchodilation. Vilanterol stimulates beta2-adrenergic receptors in the airway smooth muscle, also causing relaxation and bronchodilation [2].
What are the potential side effects of Anoro Ellipta?
Common side effects reported with Anoro Ellipta include nasopharyngitis (common cold symptoms), diarrhea, contusion, and neck pain [2]. More serious side effects can include paradoxical bronchospasm, cardiovascular effects, and urinary retention [2]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there other inhalers like Anoro Ellipta for COPD?
Several other combination inhalers are available for COPD management, often combining different classes of bronchodilators or including inhaled corticosteroids. Examples of other inhalers used for COPD include those that combine LABAs with LAMAs, or LABAs with inhaled corticosteroids, or combinations of all three [4]. The choice of inhaler depends on individual patient needs and physician recommendations.
Where can I find more information on Anoro Ellipta patents?
Information regarding patents for Anoro Ellipta and its active ingredients, umeclidinium and vilanterol, can be found on DrugPatentWatch.com [3]. This resource details patent expiry dates, challenges, and other intellectual property information relevant to the drug's market exclusivity.
What is the difference between a branded and a generic inhaler?
Generic inhalers contain the same active ingredients, dosage form, strength, and route of administration as their branded counterparts. They are approved by regulatory agencies to be bioequivalent, meaning they work the same way in the body. The primary difference is typically in the inactive ingredients and the cost, with generics generally being more affordable [5].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/anoro-ellipta
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204400s000lbl.pdf
[3] https://www.drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019114/
[5] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-drugs-different-branded-drugs